The pharmaceutical industry is rooted in the ability to research, develop, market, and distribute safe and effect drugs that meet the need of patients. In many cases pharmaceutical companies attempt to accelerate their drug development efforts by acquiring other companies for their pipeline; however, there may be missed opportunities to protect, foster, and metabolize a core asset throughout the acquisition process: innovation.
The following capstone, presented as a single case study, focuses on innovation retention and protection through the lens of an acquired organization. While plenty of research has been conducted to prescribe how companies can become more innovative, this capstone explores practical methods for protecting existing innovative assets while reviewing challenges and opportunities through an organizational dynamics lens. The overall goal of this paper is to establish a suggest framework for protecting innovation in order to maximize organizational effectiveness
